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Abstract
Background: In order to improve our understanding of the molecular pathways that mediate tumor proliferation and
angiogenesis, and to evaluate the biological response to anti-angiogenic therapy, we analyzed the changes in the protein
profile of glioblastoma in response to treatment with recombinant human Platelet Factor 4-DLR mutated protein (PF4-DLR),
an inhibitor of angiogenesis.
Methodology/Principal Findings: U87-derived experimental glioblastomas were grown in the brain of xenografted nude
mice, treated with PF4-DLR, and processed for proteomic analysis. More than fifty proteins were differentially expressed in
response to PF4-DLR treatment. Among them, integrin-linked kinase 1 (ILK1) signaling pathway was first down-regulated
but then up-regulated after treatment for prolonged period. The activity of PF4-DLR can be increased by simultaneously
treating mice orthotopically implanted with glioblastomas, with ILK1-specific siRNA. As ILK1 is related to malignant
progression and a poor prognosis in various types of tumors, we measured ILK1 expression in human glioblatomas,
astrocytomas and oligodendrogliomas, and found that it varied widely; however, a high level of ILK1 expression was
correlated to a poor prognosis.
Conclusions/Significance: Our results suggest that identifying the molecular pathways induced by anti-angiogenic
therapies may help the development of combinaatorial treatment strategies that increase the therapeutic efficacy of
angiogenesis inhibitors by association with specific agents that disrupt signaling in tumor cells.
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Introduction
The dependence of tumor growth and metastasis on angiogen-
esis provides a powerful rationale for anti-angiogenic approaches
for the treatment of glioblastoma and other solid tumors.
Targeting blood vessels in brain tumors is a particularly attractive
strategy, given their characteristic high degree of endothelial
proliferation, vascular permeability, and expression of pro-
angiogenic growth factors, [e.g. vascular endothelial growth factor
(VEGF)] [1,2,3,4].
In the case of glioblastomas, anti-angiogenic agents have
been used in combination with chemotherapy but, after a
certain amount of time, tumor growth resumes. It has recently
been suggested that cells evade anti-angiogenic therapies by
up-regulating alternative signaling circuits [5]. It is therefore
useful to identify pathways that are associated with tumor
angiogenesis and the response to anti-angiogenic therapy. This
may help in developing new specific combinatorial therapeutic
strategies.
We used a proteomic approach to investigate the ‘‘proteome
response’’ to the treatment of experimental glioblastomas with
anti-angiogenic drugs. We used Platelet Factor 4-DLR (PF4-
DLR), a peptide derived by inserting DLR mutations on a PF4
47–70aa fragment from Platelet Factor 4 that potently inhibits
angiogenesis [6].
Platelet Factor-4-DLR inhibits the binding of iodinated VEGF
or FGF-2 to cell surface receptors at much lower concentrations
than the unmodified peptide, and abrogates VEGF or FGF-2-
induced endothelial cell proliferation [6]. This inhibitor has been
widely used in human glioblastoma models, in which it
significantly inhibits tumor angiogenesis and growth. However,
depending on the dose used and the tumors stage at which it is
administered, prolonged treatment with PF4-DLR alone or in
combination leads to the development of drug resistance [7].
Receptors and intracellular kinases are involved in cancer
progression, metastatic spread and the development of resistance
to pharmacological treatments [8]. Integrin-linked kinase 1(ILK1)
is a protein dependent kinase that regulates Akt activity [9] in a
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13710
PI3K-dependent manner [10]. It is an important regulator of
tumor proliferation, invasion and angiogenesis because it increases
VEGF expression by stimulating HIF-1a via AKT phosphoryla-
tion on Ser473 [11]. It also promotes cell growth [12] and cell cycle
progression [13], and inhibits apoptosis [14]. Recent studies have
demonstrated that ILK1 is involved in glioblastoma progression
[15] and radioresistance [16].
We found that ILK1 expression is down-regulated after ten days
treatment and up-regulated after twenty days. Interestingly
treatment with PF4-DLR and an anti-ILK1 short interfering
RNA is associated with a decrease in tumor mass and a reduction
in the number of tumor vessels.
Our findings have important therapeutic implications and
suggest that combination strategies that simultaneously inhibit
different mechanisms of tumor proliferation and angiogenesis may
significantly increase therapeutic efficacy. We also analyzed the
levels of ILK1 in patients with glioblastomas, astrocytomas and
oligodendrogliomas, and found that high levels of ILK1 expression
correlate with a poor prognosis. Our data suggest that ILK1 could
represent a new specific pharmacological target to be inhibited
alone or in combination with anti-angiogenic therapies in gliomas.
Materials and Methods
Ethics Statement
Animals were used in accordance with protocols approved by
the Italian Minister for Scientific Research, protocol number 11/
07, approved on February 28, 2007. Brain tumor tissue was
obtained following written informed consent, approved by our
Internal Ethical Committee (Neurosurgery, Ospedale Maggiore
Policlinico, Milano).
Cell cultures
The human glioma cell line U87-MG (American Type Culture
Collection, Manassas, VA) was used in the animal experiments.
The cells were cultured in aMEM (Life Technologies, Inc., Grand
Island, NY) supplemented with 2 mM L-glutamine, 10% FBS, and
1000 units/ml gentamycin solution, maintained in T-25 tissue
culture flasks in 5% CO2/95% air at 37uC in a humidified
incubator. For the intracranial implantation experiments, U87-
MG cells were dispersed with a 0.05% solution of trypsin/EDTA
(Life Technologies), reaction was stopped with FBS. The cells were
washed with PBS, and adjusted to a final concentration of 56104
cells/10 ml in PBS.
Animal experiments
For the intracranial glioblastoma model, groups of ten 6-week-
old nude mice (Charles Rivers Italia, Calco, Italy) were
intracranically implanted with 50,000 human U87 glioma cells
using an open window technique [17]. Twelve days after tumor
cell injection (when an already well established and angiogenic
tumor had developed), the animals were implanted subcutaneously
with 2004 Alzet osmotic minipumps (ALZET, Cupertino, CA).
The pump reservoir was filled with 0.5 mg of the peptide in PBS.
The control groups received pumps containing PBS. The first
group of animals was sacrificed 10 days after pump implantation,
and the second group was sacrificed 20 days after pump
implantation (see Table S1).
To investigate the effect of combined treatment with PF4-DLR
and an anti-ILK1 small interference RNA, groups of 6-week-old
nude mice were implanted intracranically with 50,000 human
U87-MG glioblastoma cells (see above) and, twelve days after
tumor cells injection, they were divided into three groups: one
group was implanted with osmotic minipumps filled with 0.5 mg
of PF4-DLR in PBS, and the animals were sacrificed 20 days after
pump implantation; a second group was first implanted with
pumps filled with 0.5 mg of PF4-DLR in PBS and, 10 days after
the beginning of treatment with PF4-DLR ILK1-siRNA was
administered intrathecally with a minipump, filled with 0.2 mg of
siRNA in PBS,connected via a brain-infusion cannula stereotax-
ically placed and the combined treatment was continued for 10
days before the mice were sacrificed; finally the control group was
implanted with pumps containing PBS and sacrificed 20 days after
pump implantation (see Table S2).
At the time of sacrifice, fresh dissected brains were quickly
frozen in liquid nitrogen and stored at 280uC. All of the animal
experiments were repeated at least three times.
Sample preparation for 2D-PAGE and gel analysis
All of the tissues were mechanically lysed at 4uC in CHAPS
buffer [CHAPS 4%, 5 mM Tris, pH 8.8, 0.05% protease
inhibitor cocktail (Sigma)] using a glass potter, and the samples
were centrifuged at 2000 g for 15 minutes at 4uC in order to
eliminate aggregates and debris and then stored at 220uC. The
protein concentrations in each sample were measured by means
of a DC Bio-Rad assay. A total of 900 mg of proteins from each
sample was precipitated with cold acetone and resuspended in
thiourea buffer (7 M urea, 2 M thiourea 2% CHAPS, 2% ASB-
14, 5% glycerol, 40 mM DTT, 4 mM TCEP, 1% 3–10 IPG
buffer, Amersham), and the samples were mixed overnight at 4uC
in the dark and clarified by centrifugation at 16000 g for 15
minutes at 4uC. The supernatant was first separated by isoelectric
focusing over a pH range of 3–10 using precast first-dimension
drystrip 3–10 NL 18 cm (Amersham) following a multi-step
protocol for 90,000 Vht (Protean IEF cell, Biorad). The first-
dimension strip was equilibrated in 50 mM Tris, pH 8.8, 6 M
urea, 30% glycerol, 2% SDS plus 16 mM DTT for 20 minutes,
and then plus 25 mM iodioacetamide for 15 minutes, and loaded
on a large format (22622 cm) 9–16% acrylamide gel to separate
the proteins by molecular weight. Second-dimension runs were
performed using Biorad XL cells at 30 V 1 h, 300 V 4 h at a
constant temperature of 18uC. Protein spots were revealed using
home-made blue Coomassie staining, and the gel images were
acquired by means of an Image scanner at 300 DPI resolution and
analyzed using Image2D Master Platinum software (both from
Amersham). At least seven gels per condition were included in the
analysis.
Normalized spot volume values were studied using SPSS
software version 13.0 for statistical analysis (SPSS Inc.). In brief,
the data for each spot match set were analyzed using a box-plot
test in order to eliminate outliers, a K-S test to check normal
distribution, an F test to analyze the variance, and finally Student’s
t test to compare the mean values, which were considered
significant when p,0.05.
Trypsin digests of protein spots and MALDI-TOF-MS
Protein spots of interest were excised from the gels, reduced,
alkylated, and digested overnight with bovine trypsin (Roche
Diagnostic), as previously described [18], and a 1 ml aliquot of the
supernatant underwent mass analysis using the dried droplet
technique and a-cyano-4-hydroxycinnamic acid as matrix; the
mass spectra were obtained using a MALDI–TOF Voyager- DE
STR mass spectrometer (Applied Biosystems). Alternatively, gel
fragments were further extracted and the resulting peptide mixture
underwent a single desalting/concentration step before mass
spectrometric analysis over mZipTipC18 (Millipore Corporation).
The spectra were internally calibrated using trypsin autolysis
products, and processed using Data Explorer software. The
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proteins were unambiguously identified by searching against a
comprehensive non-redundant protein database using the Pro-
Found and
MASCOT programs [19]; one missed cleavage per peptide was
allowed, and an initial mass tolerance of 50 ppm was used in all
searches.
Western blot analysis and antibodies
For Western blot analysis, 700 mg of proteins from each
sample were precipitated twice in cold acetone 80% and 0.2 mM
DTT for 30 minutes at 16,000 g and 4uC. The protein pellets
were resupended in 150 ml of Laemmli’s buffer, and 10 ml were
loaded onto 6–12% SDS-PAGE gels. The proteins were
transferred onto nitrocellulose membrane (Sigma) at 80 V for
120 minutes at 4uC. Primary antibodies were applied overnight
in blocking buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.1%
Tween 20, and 3% dried non-fat milk). Antibodies against
caspase 3 precursor, HSP90, PKC, ILK1, pAKT, AKT,
VEGFR and EGFR (Cell Signaling), peEF2, eEF2 and eEF2
kinase (gifts from A. Nairm.), vinculin, tubulin and actin (Sigma),
and the secondary antibodies (HRP-conjugated anti-mouse,
anti-rabbit or anti-goat) (Amersham) were used in a ratio of
1:2000. The signal was detected by an ECL detection system
(PerkinElmer Life Sciences, Emeryville, CA), captured by means
of a Versadoc 1000 digital camera (Biorad), and quantified using
ImageQuant software (Bio-Rad).
siRNA knockdown
The silencing ILK1 RNA stabilized oligonucleotides (siRNA:
sense GCACCAAUUUCGUCGUGGAUU; antisense 59-pUC-
CACGACGAAAUUGGUGCUU) were purchased from Dhar-
macon, and were used with a 21-bp non-silencing control
sequence. For the in vitro study, U87-MG cells were transfected
with lipofectamine 2000 (Invitrogen, Frederick, MD) following the
manufacturer’s instructions using 50 and 100 mM non-silencing
or siRNA with 6 ml LipofectAMINE 2000 reagent for 400,000
cells. All of the experiments were performed 48 hours after
transfection, and proliferation was assayed 96 hours after
transfection. ON TARGET-plus siRNAs for ILK1 siRNA (sense
GCACCAAUUUCGUCGUGGAUU; antisense 59pUCCAC-
GACGAAAUUGGUGCUU) or siNTC (Dharmacon) were used
for the in vivo study. The siRNAs were administered at a
concentration of 0.4 mg/kg/day in PBS.
Proliferation assay
This assay was used to test the biological activity of human
ILK1 siRNA on U87-MG cell proliferation. U87-MG cells were
plated on a 96-well plate (20,000cells/well) and cultured in the
presence of ILK1 siRNA (50 or 100 mM) and 10% serum for 24,
48 and 96 hours. The relative number of cells was calculated using
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
conversion assay (MTT test) (Promega, Madison, WI).
Production of recombinant human PF4-DLR
The COOH-terminal peptide of human PF-4-DLR (PF-4 47–
70DLR: NGRKICL-DLRAPLYKKIIKKLLES) was synthesised
on a peptide synthesizer using standard Merrifield solid-phase
synthesis protocols and t-butoxycarbonyl chemistry, and analysed
by means of reverse- phase HPLC chromatography. The peptides
used for the biological assays were further purified by dialysis using
Spectrapor 500 MW-cut-off membranes or by means of reverse-
phase purification using CI8 Sep-Pak cartridges. The identity of
the peptides was verified using MALDI-TOF-MS.
Histology, immunofluorescence and immunochemistry
For the histology studies, 10 mm sections of brains removed
from treated and untreated mice were fixed with methanol 100%
and stained with hematoxylin and eosin (Bio-Optica). Images were
acquired using a StemiDV4 microscope equipped with a AxioCam
ICc 1 camera (Zeiss). Tumor volume were measured by the
ellipsoid formula [(width26length)/2]. Between-group differences
in tumor growth were analyzed using the ANOVA with post hoc
Tukey test, with p values of ,0.05 being considered statistically
significant.
For the immunofluorescence studies, 10 mm sections were fixed
in 4% paraformaldehyde and 4% sucrose at room temperature for
10 minutes. The primary and secondary antibodies were applied
in Gelatin Detergent Buffer (GDB) buffer (30 mM phosphate
buffer, pH 7.4, containing 0.2% gelatin, 0.5% Triton X-100 and
0.8 M NaCl). The samples were stained using antibodies against
rat anti-mouse CD31 (1:50, B&D, Pharmigen, San Jose, CA). The
secondary antibody used was anti-rat Cy3-conjugated (Jacson
ImmunoResearch, West Grove, PA). All of the sections were
counterstained with DAPI (Sigma). The fluorescence images were
acquired using a confocal LSM510 Zeiss (gift from Monzino
Foundation) with a Zeiss 20x objective. All of the measurements
were made using Metamorph image analysis software (Universal
Imaging Corporation), and were expressed as mean values 6
standard error mean (SEM).
Immunohistochemical analysis was performed with the Vectas-
tain ABC system (Vector Laboratories, Burlingame, CA). In brief,
10 mm sections were air dried and methanol fixed; endogenous
peroxidase were blocked with 0.3% H2O2 in PBS for 30 minutes;
primary antibodies against rat anti-mouse CD31 (1:50, B&D,
Pharmigen, San Jose, CA) or rabbit anti-human ILK1 antigens
(1:50 Cell Signaling) were applied in GDB buffer for 2 hours at
room temperature. Secondary antibodies conjugated with biotin
were applied in GDB buffer for 1 hour at room temperature. The
slices were then incubated with ABC reagent for 30 minutes at
room temperature and subsequently treated with DAB until
brown staining appearance. Finally, the sections were stained with
hematoxylin, dehydrated in ethanol and mounted with glass
coverslips. The image were visualized with a Leica microscope
equipped with 10x and 20x objectives and images were acquired
using an AxioCam ICc 1 camera (Zeiss).
Tissue samples
The tumor tissues came from patients with astrocytomas,
oligodendrogliomas or glioblastomas, diagnosed on the basis of the
latest WHO classification of gliomas, and were obtained at the
time of surgery and stored in nitrogen vapor. Tissues were
prepared for Western Blot analysis as described before.
For the immunohistochemistry tissues from patients with
different types of tumors were analyzed by the Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA). All of the
specimens were formalin fixed and paraffin embedded. Three
5 mm thick sections were cut from each block. The paraffin
sections were deparaffined in xylene and antigen was retrieved
using sodium citrate buffer (pH 6.0) in a microwave oven three
times for five minutes each time. The sections were stained for
immunohistochemical analysis with the primary anti-mouse ILK1
antibody (see above).
Statistical analysis
Data were expressed as means with standard errors of the mean
(SEM). The significance of differences was tested by unpaired
Student t test (two means) or ANOVA with post hoc Tuckey test
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(more than two means). The SPSS statistical package version 13.0
(SPSS Inc.) was used for the analyses.
Results
Proteomic analysis of experimental glioblastoma treated
with PF4-DLR
In order to identify the changes in protein expression induced
by PF4-DLR treatment, nude mice bearing U87-MG glioblastoma
xenografts were treated using osmotic minipumps that released
0.5 mg/kg/day of peptide. Pumps were implanted 12 days after
tumor cells implantation. Animals were sacrificed for the
proteomic analysis 10 and 20 days later.
Two-dimensional SDS polyacrylamide gel electrophoresis (2D-
SDS-PAGE) was used to compare protein expression patterns in
treated and untreated tumors of the same age.
At least seven independent gels were used for matching in each
group, and a total of more than 1800 protein spots were analyzed
(Figures 1A–B and Figure S1A–B show typical 2D gels). The gels
included in the analysis were chosen on the basis of comparable
total spot numbers, and percentages and distribution parameters
as detected by the Image2D Master Platinum software (Amer-
sham).
In tumors treated with PF4-DLR for 10 days, 24 proteins were
differentially expressed (p,0.05) in response to the treatment. Of
these, 14 were up-regulated and 10 down-regulated (Figure 1A,
Table 1 and Figure S2). A set of proteins that correlate with the
inhibition of tumor growth in the response to therapy included
transforming growth factor-b induced (TGFBI), annexin A1 and
protein disulfide-isomerase, which were increased. Another set of
proteins involved in cell proliferation was also increased after 10
days of treatment. These include serotransferrin precursor,
bifunctional purine biosynthesis protein, elongation factor 1,
vinculin and septin 5 (see Table 1 and Figure S2).
Tumors treated with PF4-DLR for 20 days showed 30
differentially expressed proteins (p,0.05). Twenty four were up-
regulated and 6 down-regulated in treated tumors (Figure 1B,
Table 2 and Figure S3). Among these proteins, integrin-linked
kinase 1 (ILK1), stress-inducible protein 1 (STI1), eukaryotic
elongation factor 2 (eEF2), vinculin, fascin, pyruvate kinase M2,
transketolase, moesin, and the plasminogen precursor were found
(see Table 2 and Figure S3).
Confirmation of protein expression changes by Western
blotting
As part of validation of the proteomic analysis, the expression of
some of the identified proteins was tested by immunoblotting using
protein extracts from glioblastomas treated with PF4-DLR for 10
and 20 days. As expected, caspase 3 was decreased after 20 days of
PF4-DLR treatment when compared to untreated tumors
(Figure 2A and 2B), in agreement with the proteomic analysis.
Immunoblotting not only confirmed the up-regulation of ILK1 in
tumors treated with PF4-DLR for 20 days, but also revealed a
significant decrease in ILK1 levels after 10 days of treatment in
comparison to untreated tumors (Figure 2A and 2B).
2D gels showed three spots corresponding presumably to eEF2
protein with the same molecular weight but with different pI
values. The treated tumors showed a significant increase in the
more acidic spots. This may be due to a post-translational
modification such as protein phosphorylation. We therefore
analyzed the phosphorylation level of eEF2 using anti-phospho-
eEF2 and total eEF2 antibodies. As shown in Figure 2A and 2B,
eEF2 phosphorylation was significantly reduced after 10 days of
PF4-DLR treatment, but also significantly increased after 20 days.
In addition, we investigated the expression of eEF2 kinase and
found a significant increase after 20 days.
Finally, immunoblotting confirmed the increase in expression of
vinculin in mice treated for 20 days (Figure 2A and 2B).
PF4-DLR specifically induces ILK1 pathway activation
Among the identified proteins, we decided to concentrate on
ILK1. The kinase activity of ILK1 is stimulated by growth factors
and chemokines in a PI3 kinase-dependent manner [10]. ILK1
can also mediate the phosphorylation of a variety of intracellular
substrates, particularly protein kinase B/Akt on serine-473 [20].
We therefore, tested the levels of AKT phosphorylation in tumors
Figure 1. Two-dimensional PAGE gels analysis of PF4-DLR treated glioblastomas. In order to identify protein expression changes in mice
treated with PF4-DLR, samples of treated and untreated glioblastomas were analyzed by means of two-dimensional PAGE gels. The tissues were
prepared as described in Materials and Methods: 900 mg of protein underwent two-dimensional PAGE using a first dimension pH NL gradient of 3-
10% and a second dimension gradient of 9–16% acrylamide. The gels were stained with colloidal Coomassie blue. A) example of gel obtained from
glioblastomas treated with PF4-DLR for 10 days; B) example of gel obtained from glioblastomas treated with PF4-DLR for 20 days. At least seven gels
per condition were used to analyze protein changes. The analyzed spots and related identification numbers are shown in yellow.
doi:10.1371/journal.pone.0013710.g001
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treated with PF4-DLR. As expected, AKT phosphorylation was
decreased after 10 days of treatment and increased after 20 days
(Figures 3A and 3B).
It has been shown that growth factors receptor expression
correlates with ILK1 expression [21]. We therefore analyzed the
levels of EGFR by immunoblotting: similar to ILK1 and pAKT
expression of EGFR was reduced after 10 days of PF4-DLR
treatment and increased after 20 days (Figures 3A and 3B). On the
contrary, VEGFR2 was down-regulated by PF4-DLR after both
10 and 20 days of treatment (Figure 3A and 3B).
This may indicate that PF4-DLR, after 10 days of treatment, is
decreasing ILK1 levels by down-regulating EGFR. On the
contrary, longer treatment (20 days), led to an increase in ILK1
levels, and of down-stream pathways.
ILK1 knockdown in glioblastoma cells increases PF4-DLR
activity
We next performed knocked down experiments using specific
ILK1 siRNA and analyzed its consequences on glioma cell
proliferation and tumor development in vitro and in vivo. The
ability of ILK1-siRNA to reduce the expression of ILK1 protein
was first tested in U87-MG cells in vitro. Both 50 and 100 nM
ILK1 siRNA reduced ILK1 protein expression (NT: 100%;
scrambled 50 nM: 96.6%; scrambled 100 nM: 94.9%; siRNA
ILK1 50 nM: 50.0%; siRNA ILK1 100 nM: 41.3%) (Figure 4A).
We next measured U87 –MG proliferation. As expected ILK1
siRNA reduces cell proliferation (NT: 100%; scrambled 100 nM:
90.0%; siRNA ILK1 50 nM: 52.0; siRNA ILK1 100 nM: 47.2) to
about 50% when incubated for 48 hours in comparison with cells
transfected with scrambled control siRNA (Figure 4B).
We then tested whether the inhibitory activity of PF4-DLR can
be increased in vivo by combined treatment with PF4-DLR and
ILK1 siRNA in the experimental glioma model in mice. A first
osmotic mini-pump releasing PF4-DLR (0.5 mg/kg/day) was
implanted 12 days after tumor injection, and followed, after
additional ten days, by the implantation of a second minipump,
intrathecally connected, releasing ILK1 siRNA (0.4 mg/day).
Animals were sacrificed 10 days later. As control, some mice were
left untreated and others were treated with PF4-DLR alone for 20
days (see Table S2). As shown in Figure 4C and 4D, the expression
of ILK1 was greatly reduced in tumors when mice were treated
with ILK1 siRNA.
Untreated mice developed a large and compact tumor masses
occupying about half of the brain with a smooth and regular
margin, whereas treatment with PF4-DLR alone reduced tumor
volume to ,30% of untreated control. Combined treatment with
PF4-DLR and ILK1-siRNA further reduced the size to ,6% of
untreated control (NT: 9.161.1; DLR: 3.260.4: DLR+ILK1
siRNA: 0.660.07 mm3) (Figure 5A and 5B). The effect of PF4-
DLR and ILK1 siRNA on tumor angiogenesis was also evaluated
by staining with anti-CD31 antibody. PF4-DLR alone significantly
Table 1. DLR 10 days.
Swiss prot
TrEMBL Acc No Protein name Spot No Mw pI DLR/Ctr
Peptides
matched
Sequence
coverage
Q15063 Serotransferrin precursor 1 76.7 6.94 1.6 (p,0.05) 35/24 36.4%
P31939 Bifunctional purine biosynthesis protein 2 64.6 6.27 1.9 (p,0.05) 4/4 8.4%
O08553 Dihydropyrimidinase-related protein 2 3 61.1 5.95 0.4 (p,0.001) 20/12 28.8%
P30101 Protein disulfide-isomerase A3 precursor 4 56.7 5.98 2.0 (p,0.05 21/15 33.7%
Q9D1A2 Cytosolic nonspecific dipeptidase 5 52.7 5.43 0.6 (p,0.05) 8/8 17.0%
P06733 Alpha-enolase 6 47.0 7.01 1.9 (p,0.05) 16/7 22.6%
P26641 Elongation factor 1-gamma 7 50.0 6.25 2.3 (p,0.05) 15/10 24.5%
Q04447 Creatine kinase B-type 8 42.7 5.40 0.4 (p,0.005) 30/10 34.9%
P15105 Glutamine synthetase 9 42.0 6.47 0.6 (p,0.005) 11/7 25.3%
P05201 Aspartate aminotransferase 10 46.1 6.68 0.6 (p,0.05) 17/11 30.6%
P04083 Annexin A1 11 38.6 6.57 2.0 (p,0.005) 24/17 46.4%
P14152 Malate dehydrogenase 12 36.3 6.16 0.5 (p,0.005) 22/7 29.7%
P53810 Phosphatidylinositol transfer protein alpha 13 31.7 5.97 0.7 (p,0.05) 12/6 28.9%
Q9R1P0 Proteasome subunit alpha type 4 14 29.4 7.58 1.9 (p,0.05) 3/3 10.3%
P60174 Triosephosphate isomerase 15 26.5 6.45 1.7 (p,0.005) 23/10 41.1
P00558 Phosphoglycerate kinase 16 44.5 8.30 0.6 (p,0.005) 7/7 25.0%
Q9Z2Q6 Septin-5 17 42.7 6.21 0.7 (p,0.05) 4/4 13.8
P18206 Vinculin 18 123.6 5.50 1.6 (p,0.05) 20/20 22.7
Q15582 Transforming growth factor-beta-induced 19 74.6 7.62 2.2 (p,0.05) 9/8 13.8%
Q16658 Fascin 20 54.4 6.84 2.4 (p,0.005) 9/9 20.1%
Q9CZU6 Citrate synthase 21 51.7 8.72 2.4 (p,0.05) 5/5 12.7%
P19157 Glutathione S-transferase P 1 22 23.5 7.69 0.4 (p,0.05) 6/5 32.1%
P62334 26S protease regulatory subunit S10B 23 44.1 7.09 1.8 (p,0.001) 7/7 20.8%
P60174 Proteasome subunit alpha type 6 24 26.5 6.45 1.7 (p,0.005) 19/10 43.1%
List of differentially expressed proteins identified by MALDI-TOF after two- dimensional PAGE analysis of glioblastomas treated with PF4-DLR for ten days or left
untreated. The experimental MW and pI are indicated for each protein.
doi:10.1371/journal.pone.0013710.t001
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reduced the number of vessels, but the reduction was even greater
after the combined treatment (NT: 64.866.5; DLR: 31.862.1;
DLR+ILK1 siRNA: 17.161.5) (Figure 5C and D).
ILK1 expression in human gliomas
We measured ILK1 expression in human glioblastomas (GBM),
astrocytomas and oligodendrogliomas by immunoblotting. Ten
GBM, 12 oligodendrogliomas and 8 astrocytomas were analyzed.
Expression of ILK1 and its major substrate, pAKT, varied as
shown in Figure 6A and 6C. Tumors expressed low, medium or
high levels of ILK1 and pAKT, and this was confirmed by
immunohistochemistry (Figure 6B shows two different oligoden-
drogliomas expressing low and high levels of ILK1).
We also correlated ILK1 expression levels of tumors to the time
of recurrence (NR: long-term recurrence, more than one year after
initial treatment, R: short-term recurrence, less than four months
after initial treatment). ILK1 was significantly more expressed in
the subset of patients with early recurrence in all three types of
glioma (Figures 6E and 6F; astrocytomas: NR 0.4760.12 R
2.5160.9; oligodendrogliomas NR 0.660.13 R 1.260.2; GBMs
NR 0.460.07 R 0.960.15). This suggests that gliomas expressing
high ILK1 levels are more aggressive.
Discussion
Previous experiments have shown that PF4-DLR reduces
angiogenesis and inhibits tumor growth in a dose-dependent
manner in the U87-MG model. We identified 24 proteins that
were differentially expressed in the tumors treated with PF4-DLR
for 10 days (14 up-regulated and 10 down-regulated), some of
which are known to be involved in tumor development, and may
constitute potential prognostic markers or therapeutic targets.
Annexin A1 (ANXA1), which plays an important role in
regulating cell growth and apoptosis, was increased in treated
tumors. Reduced ANXA1 expression has been observed in
many different human malignancies, and the overexpression of
Table 2. DLR 20 days.
Swiss prot
TrEMBL Acc No Protein name Spot No Mw pI DLR/Ctr
Peptides
matched Sequencecoverage
P13639 Elongation factor 2 25 95.3 6.41 1.8 (p,0.05) 72/28 33%
P02545 Lamin A/C 26 74.1 6.57 1.4 (p,0.01) 13/13 20%
P06396 Gelsolin precursor 27 85.7 5.90 1.7 (p,0.001) 3/2 3%
P41250 Glycyl-tRNA synthetase 28 83.1 6.61 1.5 (p,0.05) 13/9 11%
P02545 Lamin A/C 29 74.1 6.57 1.6 (p,0.001) 17/14 22%
P02545 Lamin A/C 30 74.1 6.57 1.4 (p,0.001) 29/21 31%
P02545 Lamin A/C 31 74.1 6.57 1.9 (p,0.001) 22/17 30%
P18206 Vinculin 32 123.8 5.50 2.5 (p,0.001) 55/30 31%
P14618 Pyruvate kinase 33 58.0 7.96 1.5 (p,0.01) 16/11 23%
Q13418 Integrin-linked protein kinase 34 51.4 8.30 2.0 (p,0.05) 2/2 5%
P61158 Actin-like protein 3 35 47.4 5.61 1.4 (p,0.05) 16/12 38%
P17174 Aspartate aminotransferase 36 46.2 5.53 1.7 (p,0.05) 29/12 29%
P04406 GAPDH 37 36.0 8.57 0.6 (p,0.01) 13/5 23%
P21796 hVDAC-1 38 30.1 8.62 0.6 (p,0.05) 8/7 30%
P09651 hnRNP A1 39 38.8 9.26 2.3 (p,0.005) 5/4 13%
Q00623 Apolipoprotein A-I precursor 40 30.6 5.64 1.6 (p,0.05) 26/9 33%
P61106 Ras-related protein Rab-14 41 23.4 5.85 0.6 (p,0.05) 11/10 44%
P26038 Moesin 42 67.8 6.08 2.7 (p,0.01) 62/25 30%
P29401 Transketolase 43 67.9 7.58 1.8 (p,0.05) 56/16 27%
P12268 Inosine-59-monophosphate
dehydrogenase 2
44 55.8 6.44 2.0 (p,0.005) 21/10 23%
Q16658 Fascin 45 54.5 6.84 1.8 (p,0.05) 5/5 8%
P26641 Elongation Factor 1-gamma 46 50.1 6.25 1.9 (p,0.05) 27/11 17%
P09493 Tropomyosin alpha-1 chain 47 32.7 4.69 1.5 (p,0.05) 13/11 33%
P42574 Caspase-3 precursor 48 31.6 6.09 0.5 (p,0.05) 4/2 11%
P20918 Plasminogen precursor NB 49 90.8 6.21 1.4 (p,0.05) 7/6 7%
P31948 Stress-induced.phosphoprotein 1 50 62.6 6.40 1.8 (p,0.05) 24/13 27%
P23526 Adenosylhomocysteinase 51 47.7 5.92 1.6 (p,0.05) 35/15 33%
P49411 Elongation Factor Tu 52 49.5 7.26 2.0 (p,0.001) 2/2 5%
P61160 Actin-like protein 2 53 44.8 6.29 0.7 (p,0.05) 7/4 12%
P13634 Carbonic anhydrase 54 28.3 6.44 0.5 (p,0.01) 4/4 24%
List of differentially expressed proteins identified by MALDI-TOF after two dimensional PAGE analysis of glioblastomas treated with PF4-DLR for 20 days or left
untreated. The experimental MW and pI are indicated for each protein.
doi:10.1371/journal.pone.0013710.t002
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ANXA1 in tumor cells leads to growth suppression and/or
apoptosis [22].
Tumor growth and differentiation closely correlate with protein
synthesis and degradation [23–24].We detected a significant
increase of proteasome subunit alpha type 6, proteasome subunit
alpha type 4 and 26S protease regulatory subunit S10B after PF4-
DLR treatment. This indicates that anti-angiogenic treatment may
induce molecular and functional changes in the intra-cellular
proteolytic machinery.
Human glutathione S-transferase P1 (GSTP1) is highly
expressed in many human cancers including gliomas [25]. High
GSTP1 expression is associated with drug resistance, a more
aggressive clinical course, and poor patient survival. The GSTP1
plays a major role in metabolism and xenobiotic detoxification, in
which it catalyses the S-conjugation of a wide variety of
endogenous and exogenous compounds [26]. There is also
evidence indicating that it plays a role in many other important
cellular processes, including stress, growth factor-induced signal-
Figure 2. Immunoblotting validation of a set of proteins identified as being differentially expressed in glioblastomas treated with
PF4-DLR. Tissue lysates of glioblastomas treated with PF4-DLR for 10 or 20 days (D10 and D20) or untreated (c10 and c20) were prepared as
described in Materials and Methods, and the proteins were resolved on 6–12% PAGE gels. A) The proteins were blotted onto a nitrocellulose
membrane and detected with antisera raised against the individual proteins indicated on the right side of each panel. B) Histograms of the mean
band intensity (6 SEM) of each protein. *p,0.05, t test.
doi:10.1371/journal.pone.0013710.g002
Figure 3. Immunoblotting analysis of ILK1, pAKT and EGFR in PF4-DLR treated glioblastomas. Tissue lysates of the treated (D10 and
D20) and untreated (c10 and c20) tumors were prepared as described in Materials and Methods, and the proteins were resolved on 10–12% PAGE
gels. A) The proteins were blotted onto a nitrocellulose membrane and detected with antibodies raised against the individual proteins indicated on
the right side of each panel. B) Histograms of the mean band intensity (6 SEM) of each protein. *p,0.05, t test.
doi:10.1371/journal.pone.0013710.g003
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ling, cell proliferation, immune response, differentiation, cell
transformation and apoptosis [27].
The GSTP1 is phosphorylated by Ser/Thr protein kinases,
PKA and PKC, and this enhances its metabolic function [28]. We
found that the more acidic form of GSTP1 was reduced in
glioblastomas treated with PF4-DLR for 10 days. Interestingly,
Western blot analysis revealed a decrease in PKC levels which
suggests that PF4-DLR treatment regulates GSTP1 function by
reducing its phosphorylation.
After 20 days of treatment, glioblastomas are still responsive to
PF4-DLR. However, if treatment is prolonged, glioblastomas
start to activate new pathways which may induce drug
resistance. We identified 30 proteins that were differentially
expressed (p,0.05) after 20 days of PF4-DLR treatment of
which 24 were up-regulated and six down-regulated (Figure 1B
and Table 2). As most of these proteins seem to be functionally
involved in positively regulating tumor growth, glioblastomas
may develop resistance to PF4-DLR by regulating this specific
set of proteins.
There was a significant increase of the most acidic of the three
spots corresponding to elongation factor 2 (eEF2). This is
compatible with post-translational modifications of eEF2 through
phosphorylation after PF4-DLR treatment, as previously demon-
strated for eEF2. There is evidence that CaM-dependent
phosphorylation of eEF2 is associated with cell proliferation in
rat glia and gliomas [29]. We found that eEF2K expression is only
increased by PF4-DLR treatment after 20 days. We also found an
up-regulation of vinculin and fascin, which are key elements of cell
motility. Increased expression of these proteins promotes cell
migration and metastases [30].
The significance of ILK1 expression after PF4-DLR treatment
was investigated in greater detail. ILK1 was down-regulated in
glioblastomas treated with PF4-DLR for 10 days, but up-regulated
after 20 days. This suggested that ILK1 expression correlates with
treatment response, at least in our experimental model. ILK1 is a
protein involved in intracellular signal transduction of integrins
and growth factor receptors. In some tumors, increased ILK1
levels are required for cell growth/survival, cell cycle progression,
Figure 4. Characterization of specific siRNA for ILK1. A) U87 cells were transiently transfected with ILK1-specific siRNA using Lipofectamine
2000 or nontransfected (NT) as described in Materials and Methods, and harvested 48 h later; untreated cells or a non-silencing scrambled siRNA (Scr)
were included as controls. ILK1 expression was specifically reduced in the cells transfected with ILK1 siRNA. Histogram shows of the mean band
intensity (6 SEM) of each protein. **p,0.01, one-way ANOVA with post hoc Tuckey test.B). Effect of the administration of ILK1 siRNA in vitro using the
MTT test of cell proliferation. ILK1 siRNA 50 nM and 100 nM respectively led to the 48% and 53% inhibition of cell proliferation (columns 3 and 4);
100 nM of scrambled siRNA (Scr 100 nM) did not reduce cell proliferation (compare columns 1 and 2). NT: not transfected. Histogram shows mean %
of assorbance at 290 nm. **p,0.01, one-wayANOVA with post hoc Tuckey test. C and D) Effect of the administration of ILK1 siRNA in vivo;
representative immunohistochemistry (C) (Scale bar = 10 mm) and Western Blot (D) analysis of ILK1 expression in tumors from untreated mice (ctrl),
and mice treated with PF4-DLR alone (DLR) or PF4-DLR plus ILK1 siRNA (DLR siRNA ILK1). ILK1 levels were significantly reduced in the mice treated
with ILK1 siRNA. Histogram in D shows of the mean band intensity (6 SEM) of each protein. **p,0.01, one-way ANOVA with post hoc Tuckey test.
doi:10.1371/journal.pone.0013710.g004
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invasion and migration, and tumor angiogenesis [21,31,32]. ILK1
overexpression in tumor cells induces the acquisition of an invasive
phenotype and cell transformation. The role and regulation of
ILK1 in gliomas has only been partially studied. A link with tumor
cell invasion has been proposed [33,34]. Furthermore, it can
interfere with the cellular response to anti-cancer drugs such as
resistance to gemcitabine in adenocarcinoma, an effect that is
mediated by protein kinase B/Akt [35]. In a recent study, Edwards
et al. found that inhibiting ILK1 with small molecule inhibitors
causes reduced hypoxia, decreases tumor vascular mass and
decreases functional vasculature in a mouse model of glioblastoma
[36]. Interestingly ILK1 increases the expression of VEGF which
imply that ILK1 might represent a key molecule for a positive loop
inducing angiogenesis and tumor grown.
We found an association between ILK1 levels and AKT
phosphorylation at Ser473, which indicates that PF4-DLR
treatment for 10 days reduces glioblastomas growth by inhibiting
the AKT pathway. As epidermal growth factor (EGF) is a key
player in neoplastic progression [37] and AKT is a key effector of
EGFR signalling, we analyzed EGFR levels in glioblastoma
treated with PF4-DLR. Similar as observed with ILK1, 10 days of
treatment led to EGFR down-regulation, but 20 days of treatment
led to an increase in expression. The pattern of ILK1 expression
after PF4-DLR treatment therefore correlates with AKT phos-
phorylation and EGFR expression. Interestingly it has been shown
that ILK1 expression is induced by EGF [21], thus our data might
suggest that PF4-DLR is able to increase the expression of EGFR
which in turn can increase the response to EGF and the expression
of ILK1.
The approach to target ILK1 is also supported by Edwards
et al. They [36] demonstrated that inhibition of ILK1 alone is able
to delay but not to stop tumor grown. We therefore decided to
inhibit ILK1 using siRNA in addition to PF4-DLR administration
in order to investigate whether this will further improve
therapeutic efficacy in vivo over PF4-DLR alone.
At this point we need to clarify if after 10 days of treatment with
PF4-DLR alone it is required to continue the anti-angiogenic
therapy in association with ILK1 knock down or it is sufficient to
continue only knocking down ILK1 to block or eradicate the
tumor. In any case we think that the most important point is
design effective combination treatment; this because the current
opinion is that to eradicate tumor a single agent therapy is not
enough.
We believe that the synergism of angiogenesis inhibitors with
ILK1 inhibitors (such as PF4-DLR and ILK1 siRNA) should be
tested using small molecular inhibitors blocking ILK1 function and
not siRNA. Synthetic siRNA are extremely expensive and not
likely to be used for systemic administration in the clinic.
It has been found that the overexpression of kinase-inactive ILK
increases the sensitivity of EGFR-resistant hepatoma cell lines to
Figure 5. Effect of PF4-DLR + siRNA ILK1 treatment on glioblastomas development in vivo. A) Representative hematoxylin-eosin stained
histological sections of brains from mice xenografted with U87-MG and treated or not (NT) with PF4-DLR or PF4-DLR plus ILK1 siRNA (PF4-DLR +
siRNA ILK1). Scale bar = 1 mm. B) Tumor volumes were quantified from six different brains per group, and the results expressed as mean values 6
SEM. Significant differences between groups are indicated (one-way ANOVA followed by Tukey’s post hoc test, **p, 0.05 PF4-DLR versus NT; 11p,
0.05 PF4-DLR + siRNA ILK1 versus PF4-DLR). C) Representative image of vessel staining (blue: DAPI, red: anti CD31) and immunohistochemestry of
CD31. Scale bar 20 mm. D) Vessels were counted in the tumor area and were found significantly reduced in animals treated with PF4-DLR or PF4-DLR
plus ILK1 siRNA (PF4-DLR + siRNA ILK1). Significant differences between groups are indicated (one-way ANOVA followed by Tukey’s post hoc test
**p,0.05 PF4-DLR versus NT; 11p,0.05 PF4-DLR + siRNA ILK1 versus PF4-DLR).
doi:10.1371/journal.pone.0013710.g005
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the EGFR inhibitors erlotinib, gefitinib and cetuximab in vitro and
in vivo [38]. These data demonstrate that inhibiting ILK activity
may represent a novel mechanism for overcoming resistance to
EGFR inhibitors.
ILK1 expression often correlates with the malignancy and poor
survival in a number of tumors [39] including gliomas [34]. In our
study, ILK1 expression seems to be associated with early
recurrence in 3 glioma types. This finding suggests that ILK1
levels are related to tumor aggressiveness and its tendency to
progress.
In conclusion, we found that ILK1 is involved in tumor
response to anti-angiogenic therapy with PF4-DLR in a
xenografted model of glioblastoma. Furthermore, its expression
seems to be associated with the aggressiveness of the disease.
Combined therapy associating anti-angiogenesis with inhibition of
ILK1 may significantly enhance efficacy. This could represent a
new venue for the development therapies for malignant glioma.
Supporting Information
Figure S1 Two-dimensional PAGE gels analysis of PF4-DLR
treated glioblastomas. In order to identify protein expression
changes in mice treated with PF4-DLR, samples of treated and
untreated glioblastomas were analyzed by means of two-
Figure 6. Immunoblotting analysis of ILK1 and pAKT levels in biopsies from patients. The expression level of ILK1 and pAKT were
analyzed in biopsies from patients with glioblastomas (G), oligodendrogliomas (O) or astrocytomas (A). The tissue lysates were prepared as described
in Materials and Methods, and the proteins separated in 10% gels. A) Proteins blotted onto a nitrocellulose membrane and detected using antibodies
raised against the individual proteins indicated on the left side of each panel. B) Representative immunohistochemistry of ILK1 levels in different
biopsies. C and D) The graphs show histological ILK1 and pAKT levels in different patients with the same type of tumor. E and F) Patients divided on
the basis of the time of recurrence (NR: long-term recurrence, more than one year after treatment; R: short-term recurrence, less than four months
after treatment). The histograms indicate the mean band intensity (6 SEM) for each protein. *p,0.05, t test. The expression of ILK1 and pAKT was
significantly upregulated in the subset of patients with a poor prognosis, regardless of the type of glioma.
doi:10.1371/journal.pone.0013710.g006
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dimensional PAGE gels. A) example of gel obtained from
untreated glioblastomas which has been compared with PF4-
DLR treated tumor for 10 days, same age; B) example of gel
obtained from untreated glioblastomas which has been compared
with PF4-DLR treated tumor for 20 days, same age.
Found at: doi:10.1371/journal.pone.0013710.s001 (8.01 MB TIF)
Figure S2 List of differentially expressed proteins identified by
MALDI-TOF after two- dimensional PAGE analysis by compar-
ing glioblastomas treated with PF4-DLR for 10 days with
corresponding untreated tumors. The graph indicates the ratio
PF4-DLR treated/untreated tumors (PF4-DLR/Crtl) normalized
spot volume values of the identified proteins.
Found at: doi:10.1371/journal.pone.0013710.s002 (3.13 MB TIF)
Figure S3 List of differentially expressed proteins identified by
MALDI-TOF after two- dimensional PAGE analysis by compar-
ing glioblastomas treated with PF4-DLR for 20 days with
corresponding untreated tumors. The graph indicates the ratio
PF4-DLR treated/untreated tumors (PF4-DLR/Crtl) normalized
spot volume values of the identified proteins.
Found at: doi:10.1371/journal.pone.0013710.s003 (2.68 MB TIF)
Table S1 Proteomic analysis scheme.
Found at: doi:10.1371/journal.pone.0013710.s004 (0.04 MB
DOC)
Table S2 ILK1 knockdown experiment scheme.
Found at: doi:10.1371/journal.pone.0013710.s005 (0.03 MB
DOC)
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